CORESTEM Inc (166480) - Total Liabilities

Latest as of September 2025: ₩72.65 Billion KRW ≈ $49.24 Million USD

Based on the latest financial reports, CORESTEM Inc (166480) has total liabilities worth ₩72.65 Billion KRW (≈ $49.24 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of CORESTEM Inc to assess how effectively this company generates cash.

CORESTEM Inc - Total Liabilities Trend (2014–2024)

This chart illustrates how CORESTEM Inc's total liabilities have evolved over time, based on quarterly financial data. Check CORESTEM Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.

CORESTEM Inc Competitors by Total Liabilities

The table below lists competitors of CORESTEM Inc ranked by their total liabilities.

Company Country Total Liabilities
Emkay Global Financial Services Limited
NSE:EMKAY
India Rs15.74 Billion
Bubs Australia Ltd
AU:BUB
Australia AU$24.72 Million
Franklin Street Properties Corp
NYSE MKT:FSP
USA $285.91 Million
Harboes Bryggeri A/S
CO:HARB-B
Denmark Dkr633.91 Million
LEFORM
KLSE:0266
Malaysia RM217.06 Million
Thai Wacoal Public Company Limited
BK:WACOAL
Thailand ฿981.78 Million
Histeel
KO:071090
Korea ₩117.56 Billion
Ittifak Holding A.S.
IS:LRSHO
Turkey TL9.13 Billion

Liability Composition Analysis (2014–2024)

This chart breaks down CORESTEM Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is CORESTEM Inc worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.27 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.79 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.64 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how CORESTEM Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for CORESTEM Inc (2014–2024)

The table below shows the annual total liabilities of CORESTEM Inc from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 ₩68.86 Billion
≈ $46.67 Million
+16.74%
2023-12-31 ₩58.99 Billion
≈ $39.98 Million
+58.78%
2022-12-31 ₩37.15 Billion
≈ $25.18 Million
-62.55%
2021-12-31 ₩99.22 Billion
≈ $67.24 Million
-2.33%
2020-12-31 ₩101.59 Billion
≈ $68.84 Million
+263.43%
2019-12-31 ₩27.95 Billion
≈ $18.94 Million
+3.43%
2018-12-31 ₩27.03 Billion
≈ $18.31 Million
+7.80%
2017-12-31 ₩25.07 Billion
≈ $16.99 Million
+32.22%
2016-12-31 ₩18.96 Billion
≈ $12.85 Million
+59.12%
2015-12-31 ₩11.92 Billion
≈ $8.08 Million
-29.97%
2014-12-31 ₩17.02 Billion
≈ $11.53 Million
--

About CORESTEM Inc

KQ:166480 Korea Biotechnology
Market Cap
$63.21 Million
₩93.28 Billion KRW
Market Cap Rank
#20973 Global
#1297 in Korea
Share Price
₩3320.00
Change (1 day)
+1.84%
52-Week Range
₩1060.00 - ₩3975.00
All Time High
₩32150.00
About

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatm… Read more